Vestnik dermatologii i venerologiiVestnik dermatologii i venerologiiВестник дерматологии и венерологии0042-46092313-6294Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov137010.25208/vdv1370GUIDELINES FOR PRACTITIONERSВ ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУResearch ArticleClindamycin/benzoyl peroxid gel in mild-to-moderate acneКлиндамицин/бензоила пероксид гель в лечении акне легкой и средней степеней тяжестиhttps://orcid.org/0000-0003-2482-17542500-7989OlisovaOlga Yu.ОлисоваОльга Юрьевна
Russian Federation

MD, Dr. Sci. (Med.), Professor, Corresponding member of the Russian Academy of Sciences

д.м.н., профессор, член-корреспондент РАН

olisovaolga@mail.ruhttps://orcid.org/0000-0001-9478-58388499-0506AnpilogovaEkaterina M.АнпилоговаЕкатерина Михайловна
Russian Federation

MD, Cand. Sci. (Med.)

к.м.н.

truelass@hotmail.comI.M. Sechenov First Moscow State Medical University (Sechenov University)Первый МГМУ им. И.М. Сеченова (Сеченовский Университет)State Research Center of Dermatovenereology and CosmetologyГосударственный научный центр дерматовенерологии и косметологии010220232602202399155611509202220122022Copyright ©; 2023, Olisova O.Y., Anpilogova E.M.Copyright ©; 2023, Олисова О.Ю., Анпилогова Е.М.2023Olisova O.Y., Anpilogova E.M.Олисова О.Ю., Анпилогова Е.М.https://creativecommons.org/licenses/by/4.0https://vestnikdv.ru/jour/article/view/1370

Acne is a widespread inflammatory disease affecting the pilosebaceous follicles of the skin. It mostly affects teenagers and, in most cases, clinical healing occurs as patients grow up. However, 10–40% of adults may have acne tarda. Due to the fact that face is one of the favorite locations of rashes, acne significantly worsens the quality of life, as a result of which patients develop social phobia, anxiety disorders, depression and even suicidal ideas, which requires a personalized approach to prescribing highly effective treatment. According to world recommendations, regardless of the severity of acne, almost all patients are shown the use of local remedies. In our pharmaceutical market, the choice of this group of drugs is quite limited. However, in September 2022, a new drug appeared in the arsenal of Russian dermatologists, which is a combination of benzoyl peroxide and clindamycin. This review presents the accumulated experience of almost 20 years of foreign colleagues who have been successfully using a combination of benzoyl peroxide and clindamycin in the treatment of mild-to-moderate acne.

Акне — широко распространенное воспалительное заболевание сально-волосяных фолликулов. Как правило, развивается в подростковом возрасте и в большинстве случаев клиническое излечение происходит по мере взросления больных. Однако у 10–40% лиц зрелого возраста могут наблюдаться acne tarda. Ввиду того что одной из излюбленных локализаций высыпаний является лицо, акне значительно ухудшают качество жизни, вследствие чего у больных развиваются социофобия, тревожные расстройства, депрессии и даже суицидальные идеи, что требует персонифицированного подхода к назначению высокоэффективного лечения. Согласно мировым рекомендациям, вне зависимости от степеней тяжести акне практически всем пациентам показано применение местных средств. На отечественном фармацевтическом рынке выбор этой группы препаратов достаточно ограничен. Однако в сентябре 2022 г. в арсенале российских дерматологов появился новый препарат, представляющий собой комбинацию бензоила пероксида и клиндамицина. В настоящем обзоре приведен накопленный за почти 20 лет опыт зарубежных коллег, которые с успехом применяют сочетание бензоила пероксида и клиндамицина в лечении акне легкой и средней степеней тяжести.

acnebenzoyl peroxidclindamycintreatmentакнебензоила пероксидклиндамицинлечениеThe work is supported by the Pharmaceutical Сompany LLC “Jadran”.Исследование проведено при финансовой поддержке ООО «Ядран».Tan JKД, Stein Gold LF, Alexis AF, Harper JC. Current Concepts in Acne Pathogenesis: Pathways to Inflammation. Semin Cutan Med Surg. 2018;37(3S):60–62. doi: 10.12788/j.sder.2018.024Harper JC. Acne vulgaris: What's new in our 40th year. J Am Acad Dermatol. 2020;82(2):526–527. doi: 10.1016/j.jaad.2019.01.092Tan JKL, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3–12. doi: 10.1111/bjd.13462Borovaya A, Olisova O, Ruzicka T, Sardy M. Does isotretinoin therapy of acne cure or cause depression? Int J Dermatol. 2013;52(9):1040–1052. doi: 10.1111/ijd.12169Dréno B, Bettoli V, Araviiskaia E, Sanchez Viera M, Bouloc A. The influence of exposome on acne. J Eur Acad Dermatol Venereol. 2018;32(5):812–819. doi: 10.1111/jdv.14820Penso L, Touvier M, Deschasaux M, Szabo de Edelenyi F, Hercberg S, Ezzedine K, et al. Association Between Adult Acne and Dietary Behaviors: Findings From the NutriNet-Santé Prospective Cohort Study. JAMA Dermatol. 2020;156(8):854–862. doi: 10.1001/jamadermatol.2020.1602Zhang JZ, Xiang F, Yu SR, Luo D, Li TT, Kang XJ. Association between acne and smoking: systematic review and meta-analysis of observational studies. Chin Med J (Engl). 2021;134(15):1887–1888. doi: 10.1097/CM9.0000000000001286Krutmann J, Moyal D, Liu W, Kandahari S, Lee GS, Nopadon N, et al. Pollution and acne: is there a link? Clin Cosmet Investig Dermatol. 2017;10:199–204. doi: 10.2147/CCID.S131323Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton S, Brand-Miller J. Acne vulgaris: a disease of Western civilization. Arch Dermatol. 2002;138(12):1584–1590. doi: 10.1001/archderm.138.12.1584Eichenfield LF, Del Rosso JQ, Mancini AJ, Cook-Bolden F, Stein Gold L, Desai S, et al. Evolving perspectives on the etiology and pathogenesis of acne vulgaris. J Drugs Dermatol. 2015;14(3):263–272.Kircik LH. Advances in the Understanding of the Pathogenesis of Inflammatory Acne. J Drugs Dermatol. 2016;15(1):7–10.Li X, He C, Chen Z, Zhou C, Gan Y, Jia Y. A review of the role of sebum in the mechanism of acne pathogenesis. J Cosmet Dermatol. 2017;16(2):168–173. doi: 10.1111/jocd.12345Zouboulis CC, Jourdan E, Picardo M. Acne is an inflammatory disease and alterations of sebum composition initiate acne lesions. J Eur Acad Dermatol Venereol. 2014;28(5):527–32. doi: 10.1111/jdv.12298Tax G, Urbán E, Palotás Z, Puskás R, Kónya Z, Bíró T, et al. Propionic Acid Produced by Propionibacterium acnes Strains Contributes to Their Pathogenicity. Acta Derm Venerol. 2016;96(1):43–49. doi: 10.2340/00015555-2154Jahns AC, Eilers H, Alexeyev OA. Transcriptomic analysis of Propionibacterium acnes biofilms in vitro. Anaerobe. 2016;42:111–118. doi: 10.1016/j.anaerobe.2016.10.001Spittaels K, Coenye T. Developing an in vitro artificial sebum model to study Propionibacterium acnes biofilms. Anaerobe. 2018;49:21–29. doi: 10.1016/j.anaerobe.2017.11.002Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Res. 2018;7:F1000 Faculty Rev-1953. doi: 10.12688/f1000research.15659.1Liu PF, Nakatsuji T, Zhu W, Gallo RL, Huang CM. Passive immunoprotection targeting a secreted CAMPF factor of Propionibacterium acnes as a novel immunotherapeutic for acne vulgaris. Vaccine. 2011;29(17):3230–3238. doi: 10.1016/j.vaccine.2011.02.036Firlej E, Kowalska W, Szymaszek K, Roliński J, Bartosińska J. The Role of Skin Immune System in Acne. J Clin Med. 2022;11(6):1579. doi: 10.3390/jcm11061579Del Rosso JQ, Kircik LH. The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician? J Drugs Dermatol. 2013;12(8 Suppl):109–115.Fischer K, Tschismarov R, Pilz A, Straubinger S, Carotta S, McDowell A, et al. Cutibacterium acnes Infection Induces Type I Interferon Synthesis Through the cGAS-STING Pathway. Front Immunol. 2020;11:571334. doi: 10.3389/fimmu.2020.571334Dréno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31 (Suppl 5):8–12. doi: 10.1111/jdv.14374Fabbrocini G, Cacciapuoti S, Monfrecola G. A Qualitative Investigation of the Impact of Acne on Health-Related Quality of Life (HRQL): Development of a Conceptual Model. Dermatol Ther (Heidelb). 2018;8(1):85–99. doi: 10.1007/s13555-018-0224-7Stamu-O'Brien C, Jafferany M, Carniciu S, Abdelmaksoud A. Psychodermatology of acne: Psychological aspects and effects of acne vulgaris. J Cosmet Dermatol. 2021;20(4):1080–1083. doi: 10.1111/jocd.13765Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973. doi: 10.1016/j.jaad.2015.12.037Hauk L. Acne Vulgaris: Treatment Guidelines from the AAD. Am Fam Physician. 2017;95(11):740–741.Kircik LH. The role of benzoyl peroxide in the new treatment paradigm for acne. J Drugs Dermatol. 2013;12(6):73–76.Kurokawa I, Nishijima S, Kawabata S. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur J Dermatol. 1999;9(1):25–28.Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148(3):467–478. doi: 10.1046/j.1365-2133.2003.05067.xCoates P, Vyakrnam S, Eady EA, Jones CE, Cove JH, Cunliffe WJ. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol. 2002;146(5):840–848. doi: 10.1046/j.1365-2133.2002.04690.xDumont-Wallon G, Moyse D, Blouin E, Dréno B. Bacterial resistance in French acne patients. Int J Dermatol. 2010;49(3):283–288. doi: 10.1111/j.1365-4632.2009.04270.xBettoli V, Borghi A, Rossi R, Ferroni M, Rigolin F, Virgili A. Antibiotic Resistance of Propionibacteria. Dermatology. 2006;212(2):206–207. doi: 10.1159/000090665Eady AE, Cove JH, Layton AM. Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am J Clin Dermatol. 2003;4(12):813–831. doi: 10.2165/00128071-200304120-00002Karadag AS, Aslan Kayıran M, Wu CY, Chen W, Parish LC. Antibiotic resistance in acne: changes, consequences and concerns. J Eur Acad Dermatol Venereol. 2021;35(1):73–78. doi: 10.1111/jdv.16686Del Rosso JQ, Webster GF, Rosen T, Thiboutot D, Leyden JJ, Gallo R, et al. Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use. J Clin Aesthet Dermatol. 2016;9(4):18–24.Ross JI, Eady EA, Cove JH, Jones CE, Ratyal AH, Miller YW, et al. Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associated with mutations in 23S rRNA. Antimicrob Agents Chemother. 1997;41(5):1162–1165. doi: 10.1128/AAC.41.5.1162Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2 Suppl 1):S1–S23. doi: 10.1016/j.jaad.2017.09.078Jacobs A, Starke G, Rosumeck S, Nast A. Systematic review on the rapidity of the onset of action of topical treatments in the therapy of mild-to-moderate acne vulgaris. Br J Dermatol. 2014;170(3):557–564. doi: 10.1111/bjd.12706Kawashima M, Sato S, Furukawa F, Matsunaga K, Akamatsu H, Igarashi A, et al. Twelve-week, multicenter, placebo-controlled, randomized, double-blind, parallel-group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: A secondary publication. J Dermatol. 2017;44(7):774–782. doi: 10.1111/1346-8138.13798Spížek J, Řezanka T. Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications. Biochem Pharmacol. 2017;133:20–28. doi: 10.1016/j.bcp.2016.12.001Stein Gold L. Topical Treatments in Acne Vulgaris: Guidance for the Busy Dermatologist. J Drugs Dermatol. 2015;14(6):567–572.Kuwahara K, Kitazawa T, Kitagaki H, Tsukamoto T, Kikuchi M. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci. 2005;38(1):47–55. doi: 10.1016/j.jdermsci.2005.01.002Nakano T, Hiramatsu K, Kishi K, Hirata N, Kadota JI, Nasu M. Clindamycin modulates inflammatory-cytokine induction in lipopolysaccharide-stimulated mouse peritoneal macrophages. Antimicrob Agents Chemother. 2003;47(1):363–367. doi: 10.1128/AAC.47.1.363-367.2003Горячкина М.В., Белоусова Т.А., Владимиров В.В., Вертиева Е.Ю. Клинический опыт применения 1% геля клиндамицина при папулопустулезных акне. Дерматология. Приложение к журналу Consilium Medicum. 2014;(4):10–14. [Gorjachkina MV, Belousova TA, Vladimirov VV, Vertieva EYu. Clinical experience of 1% clindamycin gel usage in papulo-pustular acne. Dermatologija. Prilozhenie k zhurnalu Consilium Medicum. 2014;(4):10–14. (In Russ.)]Nast A, Dréno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, et al. European evidence-based (S3) guideline for the treatment of acne — update 2016 — short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261–1268. doi: 10.1111/jdv.13776Asai Y, Baibergenova A, Dutil M, Humphrey S, Hull P, Lynde C, et al. Management of acne: Canadian clinical practice guideline. CMAJ. 2016;188(2):118–126. doi: 10.1503/cmaj.140665Callender VD. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne. J Drugs Dermatol. 2012;11(5):643–648.Leyden JJ, Hickman JG, Jarratt MT, Stewart DM, Levy SF. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg. 2001;5(1):37–42. doi: 10.1177/120347540100500109Langner A, Sheehan-Dare R, Layton A. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol. 2007;21(3):311–319. doi: 10.1111/j.1468-3083.2006.01884.xKo HC, Song M, Seo SH, Oh CK, Kwon KS, Kim MB. Prospective, open-label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. J Eur Acad Dermatol Venereol. 2009;23(3):245–250. doi: 10.1111/j.1468-3083.2008.02920.xGreen L, Cirigliano M, Gwazdauskas JA, Gonzalez P. The Tolerability Profile of Clindamycin 1%/Benzoyl Peroxide 5% Gel vs. Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel for Facial Acne: Results of Two Randomized, Single-Blind, Split-Face Studies. J Clin Aesthet Dermatol. 2012;5(5):16–24.Hayashi N, Kurokawa I, Siakpere O, Endo A, Hatanaka T, Yamada M, et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed-dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: A multicenter, randomized, investigator-blind, parallel-group study. J Dermatol. 2018;45(8):951–962. doi: 10.1111/1346-8138.14497Jackson JM, Fu JJ, Almekinder JL. A randomized, investigator-blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. J Drugs Dermatol. 2010;9(2):131–136.Schaller M, Sebastian M, Ress C, Seidel D, Hennig M. A multicentre, randomized, single-blind, parallel-group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild-to-moderate acne vulgaris. J Eur Acad Dermatol Venereol. 2016;30(6):966–973. doi: 10.1111/jdv.13541Kaur J, Sehgal VK, Gupta AK, Singh SP. A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris. Int J Appl Basic Med Res. 2015;5(2):106–110. doi: 10.4103/2229-516X.157155